Hsp90-Cdc37-IN-4

Hsp90-Cdc37-IN-4, a Celastrol (HY-13067) derivative, inhibits the Hsp90-Cdc37 protein-protein interaction (PPI) . Hsp90-Cdc37-IN-4 selectively inhibits casein kinase 2 (CK2), reducing phosphorylation of its substrate Cdc37 at Serine 13. Hsp90-Cdc37-IN-4 induces G0/G1 cell cycle arrest and triggers apoptosis via the mitochondrial pathway. Hsp90-Cdc37-IN-4 demonstrates potent anti-breast cancer activity[1].

Product Specifications

CAS Number

[2758818-41-4]

UNSPSC

12352005

Target

Apoptosis; Casein Kinase; HSP

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C1C(O)=C(C)C2=CC=C([C@](CC[C@]3(C)[C@@]4([H])C[C@](C)(C(NCCCOC(/C=C/C5=NC=CC=C5)=O)=O)CC3)(C)[C@@]4(C)CC6)[C@]6(C)C2=C1

Molecular Formula

C40H50N2O5

Molecular Weight

638.84

References & Citations

[1]Lulu Zhang, et al. Discovery of new celastrol derivatives with antitumor activity in vitro and in vivo by blocking Hsp90-Cdc37-kinase cycle. Eur J Med Chem. 2025 May 28.296:117827